2,648 Shares in AstraZeneca PLC (NASDAQ:AZN) Bought by Saxony Capital Management LLC

Saxony Capital Management LLC acquired a new stake in AstraZeneca PLC (NASDAQ:AZN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,648 shares of the company’s stock, valued at approximately $206,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. McClarren Financial Advisors Inc. lifted its holdings in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares during the period. GHP Investment Advisors Inc. purchased a new position in AstraZeneca during the 2nd quarter worth $26,000. Pathway Financial Advisers LLC acquired a new stake in shares of AstraZeneca in the 1st quarter worth $29,000. RFP Financial Group LLC boosted its holdings in shares of AstraZeneca by 56.3% in the first quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock valued at $33,000 after acquiring an additional 178 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its stake in shares of AstraZeneca by 40.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after acquiring an additional 146 shares during the period. 20.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. TD Cowen increased their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and an average target price of $89.75.

AstraZeneca Stock Down 0.2 %

AZN stock opened at $77.32 on Wednesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The firm has a market capitalization of $239.73 billion, a PE ratio of 37.90, a P/E/G ratio of 1.45 and a beta of 0.46. The company’s 50 day simple moving average is $81.03 and its 200-day simple moving average is $78.35.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.01. The company had revenue of $12.45 billion during the quarter, compared to the consensus estimate of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. AstraZeneca’s revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.08 earnings per share. Equities analysts expect that AstraZeneca PLC will post 4.07 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Shareholders of record on Friday, August 9th were paid a dividend of $0.49 per share. The ex-dividend date of this dividend was Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio is currently 48.04%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.